

15TH ASIA-PACIFIC PHARMA CONGRESS

July 18-20, 2018 Melbourne, Australia

New erecting perspectives for phosphodiesterase 5 inhibitors

Ashraf H Abadi

German University in Cairo, Egypt

Phosphodiesterase 5 inhibitors are mainly indicated for the treatment of erectile dysfunction. Currently approved compounds differ mainly in their pharmacokinetics profile and propensity to induce side effects caused due to cross-inhibition of other PDEs. The mechanism of action of PDE5 inhibitors includes elevating the levels of the universal messenger cGMP in different cells, thus several potential uses and indications are currently emerging including, treatment of pulmonary arterial hypertension, congestive heart failure, raynaud's disease, benign prostatic hyperplasia, enhancement of cognitive functions, enhancement of hearing, as well as prevention and treatment of different types of cancer, particularly the colorectal one. From discovery perspective, a newly emerging class is GAF domain rather than catalytic domain is also emerging. This class shows favorable properties better than classic inhibitors.

Biography

Ashraf H Abadi has completed his PhD from the College of Pharmacy, University of Florida, USA and Cairo University. He is the Head of Pharmaceutical Chemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo and former Dean of the Faculty. He has published more than 80 papers in reputed journals; 7 patents and has been serving as an Editorial Board Member and Reviewer of reputed international pharmaceutical sciences journals.

ashraf.abadi@guc.edu.eg

Notes: